Positionspapier zur Implementierung eines nationalen organisierten Programms
          in Deutschland zur Früherkennung von Lungenkrebs in Risikopopulationen mittels
          Low-Dose-CT-Screening inklusive Management von abklärungsbedürftigen
          Screening-Befunden

Hans Hoffmann; Rudolf Kaaks; Stefan Andreas; Torsten T. Bauer; Jörg Barkhausen; Volker Harth; Hans-Ulrich Kauczor; Wulf Pankow; Katrin Welcker; Jens Vogel-Claussen; Torsten Gerriet Blum; Deutsche Röntgengesellschaft (Vorstand der Deutschen
          Röntgengesellschaft: Prof. Dr. med. Konstantin Nikolaou, Prof. Dr. med. Jörg Barkhausen,
          Prof. Dr. med. Christiane Kuhl, Dr. rer. nat. Frank Anton, Dr. med. Stefan Neuman, Prof.
          Dr. med. Arnd Dörfler, PD Dr. med. Friederike Körber, Prof. Dr. rer. medic. Martin
          Fiebich, Prof. Dr. med. Gerald Antoch, Dr. med. Kerstin Westphalen, Prof. Dr. Ulrike
          Attenberger, Prof. Dr. med. Frank Wacker, Prof. Dr. med. Johannes
          Weßling); Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin (Vorstand
          der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin: Prof. Dr. med. Wolfram
          Windisch, Prof. Dr. med. Christian Taube, Prof. Dr. med. Torsten T. Bauer, Prof. Dr. med.
          Antje Prasse); Deutsche Gesellschaft für Thoraxchirurgie (Vorstand der Deutschen
          Gesellschaft für Thoraxchirurgie: Dr. med. Katrin Welcker, Dr. med. Ludger Hillejan, Prof.
          Dr. med. Hans-Stefan Hofmann, PD Dr. med. habil. Robert Scheubel, Dr. med. Erich Hecker,
          Prof. Dr. med. Corinna Ludwig, Prof. Dr. med. Thorsten Walles, Prof. Dr. med. Hauke
          Winter)

doi:10.1055/a-2178-5907

Zentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie, Table of Contents

Zentralbl Chir 2024; 149(01): 96-115
DOI: 10.1055/a-2178-5907

Thoraxchirurgie – Positionspapier

Positionspapier zur Implementierung eines nationalen organisierten Programms in Deutschland zur Früherkennung von Lungenkrebs in Risikopopulationen mittels Low-Dose-CT-Screening inklusive Management von abklärungsbedürftigen Screening-Befunden

Statement Paper on the Implementation of a National Organized Program in Germany for the Early Detection of Lung Cancer in Risk Populations Using Low-dose CT Screening Including Management of Screening Findings

Hans Hoffmann^*

¹Sektion Thoraxchirurgie, Klinikum rechts der Isar, Technische Universität München, Deutschland

,

Rudolf Kaaks^*

²Deutsches Krebsforschungszentrum, Heidelberg, Deutschland

³Translational Lung Research Center Heidelberg, Deutsches Zentrum für Lungenforschung, Deutschland

,

Stefan Andreas

⁴Lungenfachklinik Immenhausen, Deutschland

⁵Klinik für Kardiologie und Pneumologie, Universitätsmedizin Göttingen, Deutschland

⁶Deutsches Zentrum für Lungenforschung, Gießen, Deutschland

,

Torsten T. Bauer

⁷Klinik für Pneumologie, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Deutschland

,

Jörg Barkhausen

⁸Klinik für Radiologie und Nuklearmedizin, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Deutschland

,

Volker Harth

⁹Zentralinstitut für Arbeitsmedizin und Maritime Medizin, Universitätsklinikum Hamburg-Eppendorf, Deutschland

,

Hans-Ulrich Kauczor

³Translational Lung Research Center Heidelberg, Deutsches Zentrum für Lungenforschung, Deutschland

¹⁰Klinik für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Heidelberg, Deutschland

,

Wulf Pankow

¹¹Taskforce Tabakentwöhnung, Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin, Berlin, Deutschland

,

Katrin Welcker

¹²Klinik für Thoraxchirurgie, Kliniken Maria Hilf GmbH, Akademisches Lehrkrankenhaus der RWTH Aachen, Mönchengladbach, Deutschland

,

Jens Vogel-Claussen^**

¹³Institut für Diagnostische und Interventionelle Radiologie, Medizinische Hochschule Hannover, Deutschland

¹⁴Biomedical Research in Endstage and Obstructive Lung Disease Hanover (BREATH), Deutsches Zentrum für Lungenforschung, Hannover, Deutschland

,

Torsten Gerriet Blum^**

⁷Klinik für Pneumologie, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Deutschland

¹⁵Medical School Berlin, Deutschland

,

Deutsche Röntgengesellschaft (Vorstand der Deutschen Röntgengesellschaft: Prof. Dr. med. Konstantin Nikolaou, Prof. Dr. med. Jörg Barkhausen, Prof. Dr. med. Christiane Kuhl, Dr. rer. nat. Frank Anton, Dr. med. Stefan Neuman, Prof. Dr. med. Arnd Dörfler, PD Dr. med. Friederike Körber, Prof. Dr. rer. medic. Martin Fiebich, Prof. Dr. med. Gerald Antoch, Dr. med. Kerstin Westphalen, Prof. Dr. Ulrike Attenberger, Prof. Dr. med. Frank Wacker, Prof. Dr. med. Johannes Weßling), Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin (Vorstand der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin: Prof. Dr. med. Wolfram Windisch, Prof. Dr. med. Christian Taube, Prof. Dr. med. Torsten T. Bauer, Prof. Dr. med. Antje Prasse), Deutsche Gesellschaft für Thoraxchirurgie (Vorstand der Deutschen Gesellschaft für Thoraxchirurgie: Dr. med. Katrin Welcker, Dr. med. Ludger Hillejan, Prof. Dr. med. Hans-Stefan Hofmann, PD Dr. med. habil. Robert Scheubel, Dr. med. Erich Hecker, Prof. Dr. med. Corinna Ludwig, Prof. Dr. med. Thorsten Walles, Prof. Dr. med. Hauke Winter) › Author Affiliations

Abstract

Zusammenfassung

Der Prozess zur Implementierung der Lungenkrebsfrüherkennung mit Niedrigdosis-CT (LDCT) in Deutschland hat in den letzten Jahren deutlich an Dynamik gewonnen. Es wird erwartet, dass der von den Fachgesellschaften kommentierte Referentenentwurf des Bundesministeriums für Umwelt, Naturschutz, nukleare Sicherheit und Verbraucherschutz (BMUV) zur Lungenkrebsfrüherkennung noch bis Ende 2023 in Kraft tritt. Basierend auf dieser Verordnung wird der Gemeinsame Bundesausschuss (G-BA) zeitnah ein Programm zur Lungenkrebsfrüherkennung mit LDCT aufsetzten. In diesem Positionspapier stellen die im Lungenkrebs-Screening beteiligten Fachgesellschaften erstmals konkrete Eckpunkte für ein einheitliches, strukturiertes und qualitätsgesichertes Früherkennungsprogramm für Lungenkrebs in Deutschland vor, um zu diesem Prozess konstruktiv beizutragen.

Abstract

The process of implementing early detection of lung cancer with low-dose CT (LDCT) in Germany has gained significant momentum in recent years. It is expected that the ordinance of the Federal Ministry for the Environment, Nature Conservation, Nuclear Safety and Consumer Protection (BMUV) on early detection of lung cancer, which has been commented on by the professional societies, will come into effect by the end of 2023. Based on this regulation, the Federal Joint Committee (G-BA) will set up a program for early lung cancer detection with LDCT in the near future. In this position paper, the specialist societies involved in lung cancer screening present concrete cornerstones for a uniform, structured and quality-assured early detection program for lung cancer in Germany to make a constructive contribution to this process.

Schlüsselwörter

Lungenkrebs-Screening - Niedrigdosis-Computertomographie - Organisiertes Früherkennungsprogramm - Rundherd-Management

Key words

Lung Cancer Screening - Low-dose Computed Tomography - Organized Early Detection Program - Nodule Management

Full Text

References

Literatur
1 International Agency for Research on Cancer, World Health Organization. Cancer Fact Sheets. 2022. Im Internet (Stand: 22.09.2023)
2 Zentrum für Krebsregisterdaten, Robert Koch Institut. Lungenkrebs (Bronchialkarzinom). 2022. Im Internet (Stand: 22.09.2023)
3 Luengo-Fernandez R, Leal J, Gray A. et al. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013; 14: 1165-1174
4 Ellis J. The impact of lung cancer on patients and carers. Chron Respir Dis 2012; 9: 39-47
5 Bonney A, Malouf R, Marchal C. et al. Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality. Cochrane Database Syst Rev 2022; (08) CD013829
6 Aberle DR, Adams AM, Berg CD. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409
7 de Koning HJ, van der Aalst CM, de Jong PA. et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med 2020; 382: 503-513
8 Field JK, Vulkan D, Davies MPA. et al. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. Lancet Reg Health Eur 2021; 10: 100179
9 Hunger T, Wanka-Pail E, Brix G. et al. Lung Cancer Screening with Low-Dose CT in Smokers: A Systematic Review and Meta-Analysis. Diagnostics (Basel) 2021; 11: 1040
10 Deutsche Krebsgesellschaft (DKG), Deutsche Krebshilfe, AWMF. Leitlinienprogramm Onkologie: Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Langversion 2.1, Dezember 2022. AWMF-Registernummer: 020/007OL. Im Internet (Stand: 22.09.2023).
11 Herth FJF, Reinmuth N, Wormanns D. et al. [Joint Statement of the German Radiological Society and the German Respiratory Society on a Quality-Assured Early Detection Program for Lung Cancer with Low-dose CT]. Pneumologie 2019; 73: 573-577
12 Kauczor HU, Baird AM, Blum TG. et al. ESR/ERS statement paper on lung cancer screening. Eur Radiol 2020; 30: 3277-3294
13 European Respiratory Society. Open letter – Increasing the early diagnosis of lung cancer in Europe: an essential milestone to tackle the biggest cancer killer. 2022. Im Internet (Stand: 22.09.2022).
14 Institute for Quality and Efficiency in Health Care (IQWiG). Lung cancer screening with low-dose computed tomography. Extract of final report S19-02. Version 1.0, 19 October 2020. IQWiG Reports – Commission No. S19-02. Cologne, Germany. Im Internet (Stand: 22.09.2023).
15 Bundesamt für Strahlenschutz (BfS). Bericht Lungenkrebsfrüherkennung mittels LDCT – Wissenschaftliche Bewertung des Bundesamtes für Strahlenschutz gemäß § 84 Absatz 3 Strahlenschutzgesetz. BfS-35/21. Im Internet (Stand: 22.09.2023).
16 Bundesministerium für Umwelt, Naturschutz, nukleare Sicherheit und Verbraucherschutz. Lungenkrebs-Früherkennungs-Verordnung (LuKrFrühErkV). Referentenentwurf einer Verordnung über die Zulässigkeit der Anwendung der Niedrigdosis-Computertomographie zur Früherkennung von Lungenkrebs bei Rauchern. 2023. Im Internet (Stand: 22.09.2023).
17 Treskova M, Aumann I, Golpon H. et al. Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting. BMC Med 2017; 15: 162
18 Hofer F, Kauczor HU, Stargardt T. Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach. Lung Cancer 2018; 124: 189-198
19 Pastorino U, Silva M, Sestini S. et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol 2019; 30: 1162-1169
20 Doroudi M, Pinsky PF, Marcus PM. Lung Cancer Mortality in the Lung Screening Study Feasibility Trial. JNCI Cancer Spectr 2018; 2: pky042
21 Paci E, Puliti D, Lopes Pegna A. et al. Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax 2017; 72: 825-831
22 Wille MM, Dirksen A, Ashraf H. et al. Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling. Am J Respir Crit Care Med 2016; 193: 542-551
23 Infante M, Cavuto S, Lutman FR. et al. Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. Am J Respir Crit Care Med 2015; 191: 1166-1175
24 Becker N, Motsch E, Trotter A. et al. Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial. Int J Cancer 2020; 146: 1503-1513
25 Patz jr. EF, Pinsky P, Gatsonis C. et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 2014; 174: 269-274
26 Ten Haaf K, van Rosmalen J, de Koning HJ. Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials. Cancer Epidemiol Biomarkers Prev 2015; 24: 154-161
27 Gonzalez Maldonado S, Motsch E, Trotter A. et al. Overdiagnosis in lung cancer screening: Estimates from the German Lung Cancer Screening Intervention Trial. Int J Cancer 2021; 148: 1097-1105
28 Meza R, Jeon J, Toumazis I. et al. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force. JAMA 2021; 325: 988-997
29 Li M, Zhang L, Charvat H. et al. The influence of postscreening follow-up time and participant characteristics on estimates of overdiagnosis from lung cancer screening trials. Int J Cancer 2022; 151: 1491-1501
30 Rampinelli C, De Marco P, Origgi D. et al. Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis. BMJ 2017; 356: j347
31 Nekolla EA, Brix G, Griebel J. Lung Cancer Screening with Low-Dose CT: Radiation Risk and Benefit-Risk Assessment for Different Screening Scenarios. Diagnostics (Basel) 2022; 12: 364
32 Brain K, Lifford KJ, Carter B. et al. Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomised controlled trial. Thorax 2016; 71: 996-1005
33 Rasmussen JF, Siersma V, Pedersen JH. et al. Psychosocial consequences in the Danish randomised controlled lung cancer screening trial (DLCST). Lung Cancer 2015; 87: 65-72
34 van den Bergh KA, Essink-Bot ML, Borsboom GJ. et al. Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial. Eur Respir J 2011; 38: 154-161
35 van den Bergh KA, Essink-Bot ML, Borsboom GJ. et al. Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON). Br J Cancer 2010; 102: 27-34
36 Gareen IF, Duan F, Greco EM. et al. Impact of lung cancer screening results on participant health-related quality of life and state anxiety in the National Lung Screening Trial. Cancer 2014; 120: 3401-3409
37 Williamson S, Patterson J, Crosby R. et al. Communication of cancer screening results by letter, telephone or in person: A mixed methods systematic review of the effect on attendee anxiety, understanding and preferences. Prev Med Rep 2019; 13: 189-195
38 Jonas DE, Reuland DS, Reddy SM. et al. Screening for Lung Cancer With Low-Dose Computed Tomography: An Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 198. AHRQ Publication No. 20 – 05266-EF-1. Rockville (MD): Agency for Healthcare Research and Quality; 2021. Im Internet (Stand: 22.09.2023)
39 Kaaks R, Delorme S. Lung Cancer Screening by Low-Dose Computed Tomography – Part 1: Expected Benefits, Possible Harms, and Criteria for Eligibility and Population Targeting. Rofo 2021; 193: 527-536
40 Knoke JD, Shanks TG, Vaughn JW. et al. Lung cancer mortality is related to age in addition to duration and intensity of cigarette smoking: an analysis of CPS-I data. Cancer Epidemiol Biomarkers Prev 2004; 13: 949-957
41 Vlaanderen J, Portengen L, Schuz J. et al. Effect modification of the association of cumulative exposure and cancer risk by intensity of exposure and time since exposure cessation: a flexible method applied to cigarette smoking and lung cancer in the SYNERGY Study. Am J Epidemiol 2014; 179: 290-298
42 Moyer VA. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014; 160: 330-338
43 Krist AH, Davidson KW, Mangione CM. et al. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2021; 325: 962-970
44 Hüsing A, Kaaks R. Risk prediction models versus simplified selection criteria to determine eligibility for lung cancer screening: an analysis of German federal-wide survey and incidence data. Eur J Epidemiol 2020; 35: 899-912
45 Behr CM, Oude Wolcherink MJ, IJzerman MJ. et al. Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations. Pharmacoeconomics 2023; 41: 395-411
46 Toumazis I, de Nijs K, Cao P. et al. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening. JAMA Oncol 2021; 7: 1833-1842
47 Ten Haaf K, Tammemägi MC, Bondy SJ. et al. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada. PLoS Med 2017; 14: e1002225
48 UK National Screening Committee. UK NSC screening recommendation: Adult screening programme – Lung cancer. 2022. Im Internet (Stand: 22.09.2023).
49 Morgan H, Baldwin DR. Important parameters for cost-effective implementation of lung cancer screening. Br J Radiol 2023; 96: 20220489
50 Balata H, Ruparel M, OʼDowd E. et al. Analysis of the baseline performance of five UK lung cancer screening programmes. Lung Cancer 2021; 161: 136-140
51 Vogel-Claussen J, Lasch F, Bollmann BA. et al. Design and Rationale of the HANSE Study: A Holistic German Lung Cancer Screening Trial Using Low-Dose Computed Tomography. Rofo 2022; 194: 1333-1345
52 Duell M, Wiethege T. Das erweiterte Vorsorgeangebot (EVA) zur Lungenkrebsfrüherkennung – Update 2019. DGUV Forum 2020; 15-17
53 Blum TG, Morgan RL, Durieux V. et al. European Respiratory Society guideline on various aspects of quality in lung cancer care. Eur Respir J 2023; 61: 2103201
54 Deutsche Krebsgesellschaft (DKG). OncoMap – Liste der zertifizierten Krebszentren. 2023. Im Internet (Stand: 22.09.2023).
55 Deutsche Krebsgesellschaft (DKG). Jahresbericht der zertifizierten Lungenkrebszentren. Kennzahlenauswertung 2022. Auditjahr 2021/Kennzahlenjahr 2020. Im Internet (Stand: 22.09.2023).
56 American College of Radiology Committee on Lung-RADS. Lung-RADS Assessment Categories 2022. Im Internet (Stand: 22.09.2023)
57 Oudkerk M, Devaraj A, Vliegenthart R. et al. European position statement on lung cancer screening. Lancet Oncol 2017; 18: e754-e766
58 Tanner NT, Kanodra NM, Gebregziabher M. et al. The Association between Smoking Abstinence and Mortality in the National Lung Screening Trial. Am J Respir Crit Care Med 2016; 193: 534-541
59 Crosbie PA, Balata H, Evison M. et al. Implementing lung cancer screening: baseline results from a community-based ‘Lung Health Check’ pilot in deprived areas of Manchester. Thorax 2019; 74: 405-409
60 Bach PB, Gould MK. When the average applies to no one: personalized decision making about potential benefits of lung cancer screening. Ann Intern Med 2012; 157: 571-573
61 International Association for the Study of Lung Cancer (IASLC). United Kingdom-Based Smoking Cessation Program Reports That 30 Percent of Support in a Lung Cancer Screening Program: The Yorkshire Enhanced Stop Smoking Study (YESS). 2022. Im Internet (Stand: 22.09.2023).
62 Evans WK, Gauvreau CL, Flanagan WM. et al. Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model. CMAJ Open 2020; 8: E585-E592
63 Fucito LM, Czabafy S, Hendricks PS. et al. Pairing smoking-cessation services with lung cancer screening: A clinical guideline from the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco. Cancer 2016; 122: 1150-1159
64 American Lung Association. Smoking Cessation Interventions and Lung Cancer Screening. 2019. Im Internet (Stand: 22.09.2023).
65 Herth FJF, Reinmuth N, Wormanns D. et al. [Joint Statement of the German Radiological Society and the German Respiratory Society on a Quality-Assured Early Detection Program for Lung Cancer with Low-dose CT]. Pneumologie 2019; 73: 573-577
66 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). S3-Leitlinie Rauchen und Tabakabhängigkeit: Screening, Diagnostik und Behandlung. AWMF-Register Nr. 076-006. 2021. Im Internet (Stand: 22.09.2023).
67 Rabenstein A, Aydin D, Lochbühler K. [Smoking cessation interventions in clinical practice]. MMW Fortschr Med 2021; 163: 32-34
68 Ministry of Health New Zealand. The New Zealand Guidelines for Helping People to Stop Smoking. 2021. Im Internet (Stand: 22.09.2023).
69 Kastaun S, Viechtbauer W, Leve V. et al. Quit attempts and tobacco abstinence in primary care patients: follow-up of a pragmatic, two-arm cluster randomised controlled trial on brief stop-smoking advice – ABC versus 5 As. ERJ Open Res 2021; 7: 00224-2021

Supplementary Material

Supporting Information